18 June 2019, London. EMMAC, the European independent medical cannabis company, is pleased to announce that construction has started on its planned EU-GMP facility in Malta. This follows the preliminary approval from Malta Enterprise, the Maltese government’s agency focused on attracting inward investment and supporting enterprise in Malta, for the issuance of a full license (covering cultivation / production / importation / exportation) under the terms of the Production of Cannabis for Medicinal Use Act, 2018. EMMAC has secured a long-term lease on the land approved by Malta Enterprise and the Medicines Authority.
The 2,800m2 facility will be EMMAC’s importation, exportation, testing and distribution hub for Europe and other international markets.
Antonio Costanzo, CEO of EMMAC, commented: “We are excited to begin construction on our facility in Malta. This hub will form a critical part of the EMMAC network of licensed and certified facilities across multiple European jurisdictions, to facilitate the distribution of premium medical cannabis, the transfer of proprietary IP and scientific research.”
EMMAC Life Sciences Ltd is the European medical cannabis company, working to join together the latest science and research with cutting-edge cultivation, extraction and production. With supply and distribution partnerships throughout Europe, EMMAC is working to establish itself as both a thought leader in the industry, as well as the European leader in the production and supply of medical cannabis, hemp and other derivative products.
For scientific enquiries please contact email@example.com
Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz Tel: +44 (0) 20 7466 5000
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.
Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Ltd assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.